Galderma Acne Ingredient Switch Receives NDAC Review In April
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA schedules an April 15 NDAC to consider whether data in Galderma's supplemental NDA support an acceptable risk/benefit profile for nonprescription use of adapalene gel 0.1.